# **Cochrane Corner Stroke**

## MS No.: STROKE/2020/030521

Title: Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis

## Authors:

Mandy D. Müller MD<sup>1</sup>, Philippe A. Lyrer MD<sup>1</sup>, Martin M. Brown MD<sup>2</sup>, Leo H. Bonati MD<sup>1,2</sup>

## Affiliations

- 1. Department of Neurology and Stroke Center, University Hospital Basel, University of Basel, Switzerland
- 2. Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, University College London, UK

## Key words:

Carotid stenosis, carotid artery stenting, carotid endarterectomy

## **Corresponding author:**

Prof. Dr. med. Leo H. Bonati

Professor of Neurology Department of Neurology and Stroke Center Department of Clinical Research University Hospital Basel Petersgraben 4 CH-4031 Basel, Switzerland E-mail: leo.bonati@usb.ch Tel.: +41 61 2652525 FAX: +41 61 2654100

#### Introduction

Atherosclerotic stenosis of the internal carotid artery is an important cause of stroke. Carotid artery stenting (CAS) is an alternative to carotid endarterectomy (CEA) for the treatment of carotid stenosis. This review updates a previous version last published in 2012 including all randomised clinical trials (RCTs) comparing CAS to CEA for treatment of carotid stenosis.

#### Objectives

To compare the benefits and risks of CAS and CEA in patients with symptomatic or asymptomatic carotid stenosis.

#### Methods

We searched the Cochrane Stroke Group Trials Register and the following databases: CENTRAL, MEDLINE, Embase, and Science Citation Index (all last searched August 2018). We also searched ongoing trials registers and reference lists, and contacted researchers in the field. All RCTs comparing CAS with CEA for symptomatic or asymptomatic atherosclerotic carotid stenosis were included.

One review author selected trials for inclusion, assessed trial quality and risk of bias, and extracted data. A second review author independently validated trial selection and a third review author independently validated data extraction. We calculated treatment effects as odds ratios (OR) and 95% confidence intervals (CI), with endarterectomy as the reference group. We quantified heterogeneity using the I<sup>2</sup> statistic.

#### Main results

We included 22 trials involving 9753 participants and used GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology to assess the overall certainty of the evidence. We categorized our findings on symptomatic carotid stenosis as high-certainty evidence, and on asymptomatic carotid stenosis as medium-certainty evidence,.

In symptomatic carotid stenosis, CAS was associated with a higher risk of death or stroke within 30 days of treatment (periprocedural period; OR 1.70, 95% CI 1.31-2.19; p<0.0001, I<sup>2</sup>=5%; 10 trials, 5396 participants) compared with CEA. Rates of periprocedural death or stroke did not differ significantly in people <70 years (OR 1.11, 95% CI 0.74-1.64), but were significantly increased with CAS compared with CEA in patients  $\geq$ 70 years (OR 2.23, 95% CI 1.61-3.08, interaction p=0.007). CAS was associated with lower risks of myocardial infarction (OR 0.47,

95% CI 0.24-0.94; p=0.03, I<sup>2</sup>=0%), cranial nerve palsy (OR 0.09, 95% CI 0.06-0.16; p<0.00001, I<sup>2</sup>=0%), and access site haematoma (OR 0.32, 95% CI 0.15-0.68; p=0.003, I<sup>2</sup>=27%) than CEA.

CAS was associated with a significantly higher risk of the combination of periprocedural death or stroke or ipsilateral stroke during follow-up compared to CEA (OR 1.51, 95% CI 1.24-1.85; p<0.0001,  $I^2=0\%$ ; 8 trials, 5080 participants; figure). However, the rate of ipsilateral stroke beyond 30 days after treatment alone did not differ between treatments (OR 1.05, 95% CI 0.75-1.47; p=0.77,  $I^2=0\%$ ).

Among patients with asymptomatic carotid stenosis, there was a non-significant increase in periprocedural death or stroke with CAS compared with CEA (OR 1.72, 95% CI 1.00-2.97; p=0.05,  $I^2=0\%$ ; 7 trials, 3378 participants). The risk of periprocedural death or stroke or ipsilateral stroke during follow-up did not differ significantly between treatments (OR 1.27, 95% CI 0.87-1.84; p=0.22,  $I^2=0\%$ ; 6 trials, 3315 participants).

Moderate or higher carotid artery restenosis ( $\geq$ 50%) during follow-up was more common after CAS (OR 2.00, 95% CI 1.12-3.60; p=0.02, I<sup>2</sup>=44%), but the difference in risk of severe restenosis was not significant ( $\geq$ 70%; OR 1.26, 95% CI 0.79-2.00; p=0.33, I<sup>2</sup>=58%).

#### Conclusions

In patients with symptomatic carotid stenosis, CAS is associated with a higher risk of stroke or death within 30 days of treatment than CEA. This extra risk is mostly attributed to an increase in peri-procedural stroke occurring in patients  $\geq$ 70 years. Beyond 30 days after treatment, CAS is as effective in preventing recurrent stroke as CEA. However, combining procedural safety and long-term efficacy in preventing recurrent stroke, CAS is still associated with higher risks than CEA.

In people with asymptomatic carotid stenosis, there may be a small increase in the risk of stroke or death within 30 days of treatment with CAS compared to CEA.

### Implications for practice and future research

CAS can be safely offered as an alternative to CEA in patients with symptomatic carotid stenosis <70 years, provided both treatments are technically feasible. Older patients should be treated with CEA. In patients with asymptomatic carotid stenosis, the amount of evidence currently available is limited and further data from randomised trials are needed.

# Figure

Study or subgroup	Stenting	Endarterec- tomy		Odds Ratio			Weight	Odds Ratio
	n/N	n/N		М-Н,	Random, 95% CI		I	M-H, Random, 95% Cl
Kentucky 2001	1/90	1/83					0.52%	0.92[0.06,14.97]
EVA-3S 2006	32/265	20/262			+-		11.67%	1.66[0.92,2.99]
SPACE 2006	56/607	50/589					25.2%	1.1[0.73,1.63]
Regensburg 2008	5/43	0/44			•	$\rightarrow$	0.47%	12.71[0.68,237.4]
BACASS 2008	1/10	0/10			•		0.37%	3.32[0.12,91.6]
Beijing 2009	2/23	1/23		_	•	-	0.66%	2.1[0.18,24.87]
ICSS 2010	105/853	62/857			-		37.05%	1.8[1.29,2.5]
CREST 2010	61/668	42/653			+		24.07%	1.46[0.97,2.2]
Total (95% CI)	2559	2521			•		100%	1.51[1.24,1.85]
Total events: 263 (Stenting), 176 (Endarterectomy)								
Heterogeneity: Tau <sup>2</sup> =0; Chi <sup>2</sup> =6	5.15, df=7(P=0.52); I <sup>2</sup> =0%							
Test for overall effect: Z=4.03(	P<0.0001)							
		Favours stenting	0.01	0.1	1 10	100	Favours endarterector	ny

#### Analysis 1.11. Comparison 1 Stenting or endarterectomy for symptomatic carotid stenosis, Outcome 11 Primary combined safety and efficacy outcome: death or any stroke between randomisation and 30 days after treatment or ipsilateral stroke until the end of follow-up.

#### Disclosures

Professor Leo Bonati was supported in part by grants from the Swiss National Science Foundation (PBBSB-116873), the University of Basel, Switzerland, and The Stroke Association. He received grants for research projects on carotid stenosis from the Swiss National Science Foundation (32003B-156658), the University of Basel, the Swiss Heart Foundation, and AstraZeneca. Professor Martin Brown's Chair in Stroke Medicine was supported by The Reta Lila Weston Trust for Medical Research.

#### Acknowledgements

This article is based on a Cochrane Review published in The Cochrane Library 2020, Issue 2 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as new evidence emerges and in response to feedback, and The Cochrane Library should be consulted for the most recent version of the review.

#### Reference

Müller MD, Lyrer P, Brown MM, Bonati LH. Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis. Cochrane Database of Systematic Reviews 2020, Issue 2. Art. No.: CD000515. DOI: 10.1002/14651858.CD000515.pub5.